EC
LLY icon

Enhancing Capital’s Eli Lilly LLY Stock Holding History

Enhancing Capital’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.63M Hold
8,300
– – 5.66% 2
2025
Q4 		$8.92M Hold
8,300
– – 6.38% 2
2025
Q3 		$6.33M Hold
8,300
– – 4.63% 4
2025
Q2 		$6.47M Hold
8,300
– – 4.93% 3
2025
Q1 		$6.86M Hold
8,300
– – 5.48% 2
2024
Q4 		$6.41M Buy
+8,300
New +$6.87M 5.11% 2
2022
Q3 		$2.71M Hold
8,300
– – 3.35% 5
2022
Q2 		$2.69M Hold
8,300
– – 3.21% 8
2022
Q1 		$2.38M Hold
8,300
– – 2.54% 10
2021
Q4 		$2.29M Buy
+8,300
New +$2.1M 2.49% 12

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Enhancing Capital's LLY Position: Q1 2026 in Review

Enhancing Capital held its Eli Lilly (LLY) position steady in Q1 2026 at 8,300 shares worth $7.63M. The position accounts for 5.66% of the portfolio, ranked #2.

Enhancing Capital first reported a position in LLY in Q4 2021 and has held it in 10 quarters since. The position peaked at $8.92M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Enhancing Capital held 8,300 shares of Eli Lilly worth $7.63M as of Q1 2026.
  • Enhancing Capital left its Eli Lilly share count unchanged in Q1 2026.
  • Eli Lilly made up 5.66% of Enhancing Capital's portfolio in Q1 2026, its #2 holding.
  • Enhancing Capital first reported a position in Eli Lilly in Q4 2021 and has held it in 10 quarters since.
  • Enhancing Capital's Eli Lilly position peaked at $8.92M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Enhancing Capital's 13F filing for Q1 2026, filed 8 May 2026.